64 results
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
28 Mar 24
Current report (foreign)
1:21pm
platform, Vector Search has helped to supercharge the identification and creation of novel drug compounds, significantly reducing R&D timelines from
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
14 Mar 24
Current report (foreign)
8:21am
.
The Company's decrease in R&D spending reflects the previous investments to develop the internal therapeutic Talem assets, which are now in the next phase … of revenue generation, and now primarily represent BioStrand R&D. Efforts are underway to pursue out-licensing opportunities for those internally
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
14 Mar 24
Current report (foreign)
8:00am
of the Company's research and development ("R&D") investments, promoting the development of proprietary technologies like B cell Select® and DeepDisplayTM … in additional, meaningful ways, including internal R&D, acquisitions, and collaborations. There is also an emphasis on therapeutic antibody asset development
424B5
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Prospectus supplement for primary offering
5:26pm
;
any reduction or delay in government funding of research and development ("R&D");
costs of being a public company in the United States;
the Company … , and through investments in R&D.
Services
IPA is a leading biotherapeutic research and technology firm, distinguished by its proficiency in both in silico
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
14 Dec 23
Current report (foreign)
8:38am
of the Company's R&D investments, promoting the development of proprietary technologies like B cell Select® and DeepDisplayTM platforms, applicable across … discovery and development.
The Company continues to broaden its intellectual property portfolio in additional, meaningful ways, including internal R&D, acquisitions
6-K
EX-99.1
62em7ukpw
14 Dec 23
Immunoprecise Antibodies LTD. 6-K
8:03am
424B5
orcr0ui9ausfwozumjr
7 Dec 23
Prospectus supplement for primary offering
4:53pm
424B5
sij h6l6sxuevubq4nt
5 Dec 23
Prospectus supplement for primary offering
4:02pm
6-K
EX-99.1
m8gdvp6eofsfvayc69h
14 Sep 23
Current report (foreign)
8:02am
424B5
kab i9a5asb
15 Aug 23
Prospectus supplement for primary offering
5:47pm
F-3
y503bf
10 Jul 23
Shelf registration (foreign)
7:04pm
40-F
EX-99.3
hdake0xwzxtn
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.1
1yqarlx6
10 Jul 23
Annual report (Canada)
4:32pm
6-K
EX-99.1
s6bwbxkjn75
30 Mar 23
Form 51-102F3 MATERIAL CHANGE REPORT
12:53pm
6-K
EX-99.1
yhwtafiqqt6
15 Dec 22
Current report (foreign)
8:00am
6-K
EX-99.1
rersov22v
14 Sep 22
Current report (foreign)
8:31am
6-K
EX-99.1
rrsfp0j6
14 Sep 22
Immunoprecise Antibodies LTD. 6-K
8:04am
40-F
EX-99.3
tytx908q1d jniodqin
29 Jul 22
Annual report (Canada)
9:04am
40-F
EX-99.1
huwhpc0jbbcdvo cwvv
29 Jul 22
Annual report (Canada)
9:04am
6-K
EX-99.1
mshx1am3op 7v6i
29 Jul 22
Immunoprecise Antibodies LTD. 6-K
8:17am